Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 4/20 | 0.35 |
| ▸ | PTGFR | P43088 | 4/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6085993 | 0.89 | PTGS1 (0.35) | PTGS1PTGFRABCB11KDM4EMEN1 | |
| SCHEMBL6086811 | 0.88 | PTGFR (0.37) | PTGS1PTGFRABCB11KDM4EMEN1 | |
| SCHEMBL6086678 | 0.87 | ALDH1A1 (0.40) | ABCB11KDM4EMAPTTBXA2RPTGER3 | |
| SCHEMBL6085069 | 0.87 | TBXA2R (0.39) | PTGFRTBXA2RPTGER3PTGDRPTGER4 | |
| SCHEMBL8320452 | 0.83 | PRKCA (0.30) | — | |
| SCHEMBL6084704 | 0.74 | ALDH1A1 (0.41) | ABCB11KDM4EMAPTTBXA2RPTGER3 | |
| SCHEMBL6085363 | 0.73 | TBXA2R (0.39) | PTGFRMAPK1TBXA2RPTGER3PTGDR | |
| SCHEMBL7099597 | 0.73 | KDM4E (0.44) | KDM4ETBXA2RPTGER3PTGDRPTGER4 | |
| SCHEMBL6085022 | 0.71 | TBXA2R (0.41) | PTGFRTBXA2RPTGER3PTGDRPTGER4 | |
| SCHEMBL6092808 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0737185-B1 | 7-[CARBOXYALKYL OR ALKENYL]-6-[ALKYL OR ALKENYL] 3-OXO-2,4-DIOXOBICYCLO-[3.2.1] OCTANE AND DERIVATIVES THEREOF | ALLERGAN INC (US) | 1999-03-31 | — | — | EP | claimed |
| US-5416106-A | Ocular hypotensive agents | ALLERGAN, INC. (US) | 1995-05-16 | — | — | US | claimed |
| US-7019149-B2 | Thromboxane ligands without blood clotting side effects | ALLERGAN, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20050049300-A1 | Thromboxane ligands without blood clotting side effects | ALLERGAN SALES, INC. | 2005-03-03 | — | — | US | disclosed |
| US-6818779-B2 | TREATING OCULAR HYPOTENSION, HYPERTENSION, HEMORRHAGE, MYOCARDIAL ISCHEMIA, ANGINA PECTORIS, CORONARY CONTRACTION, CEREBROVASCULAR CONTRACTION AFTER SUBARACHNOIDAL HEMORRHAGE, CEREBRAL HEMORRHAGE AND ASTHMA WHICH COMPRISES ADMINISTERING | ALLERGAN, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030109571-A1 | Thromboxane ligands without blood clotting side effects | ALLERGAN SALES, INC. | 2003-06-12 | — | — | US | disclosed |
| US-6462077-B1 | OXABICYLCO COMPOUNDS; OCULAR HYPOTENSION, HYPERTENSION, HEMORRHAGE, MYOCARDIAL ISCHEMIA, ANGINA PECTORIS, CORONARY CONTRACTION, CEREBROVASCULAR CONTRACTION AFTER SUBARACH-NOIDAL HEMORRHAGE, CEREBRAL HEMORRHAGE, ASTHMA | ALLERGAN, INC. | 2002-10-08 | — | — | US | disclosed |
| WO-2000066577-A2 | BRIGDED CYCLOALKANES AS THROMBOXANE LIGANDS WITHOUT BLOOD CLOTTING EFFECTS | ALLERGAN SALES, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0737185-B1 | 7-[CARBOXYALKYL OR ALKENYL]-6-[ALKYL OR ALKENYL] 3-OXO-2,4-DIOXOBICYCLO-[3.2.1] OCTANE AND DERIVATIVES THEREOF | ALLERGAN INC (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5650431-A | 3-OXO-2,4-DIOXABICYCLO(3.2.1)OCTANE DERIVATIVES | ALLERGAN (US) | 1997-07-22 | — | — | US | disclosed |
| EP-0737185-A1 | 7- CARBOXYALKYL OR ALKENYL]-6- ALKYL OR ALKENYL] 3-OXO-2,4-DIOXOBICYCLO- 3.2.1] OCTANE AND DERIVATIVES THEREOF | Allergan (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5516791-A | VISION DEFECTS FOR TREATMENT OF HYPERTENSION OF EYES | ALLERGAN (US) | 1996-05-14 | — | — | US | disclosed |
| WO-1995018103-A1 | 7-[CARBOXYALKYL OR ALKENYL]-6-[ALKYL OR ALKENYL] 3-OXO-2,4-DIOXOBICYCLO-[3.2.1] OCTANE AND DERIVATIVES THEREOF | ALLERGAN (US) | 1995-07-06 | — | — | WO | disclosed |
| US-5416106-A | Ocular hypotensive agents | ALLERGAN, INC. (US) | 1995-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049300-A1 | Thromboxane ligands without blood clotting side effects | OXER1, TBXA2R, OXTR | PTGS1 25/4885ELANE 663/4885PTGFR 74/4885 |
| US-20030109571-A1 | Thromboxane ligands without blood clotting side effects | OXER1, TBXA2R, CBR1 | PTGS1 12/4885ELANE 666/4885PTGFR 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.